Management of TKI Therapies in Integrated Delivery Network (IDN) Pharmacies
Perspectives on drivers in treatment decisions in the management of hepatocellular carcinoma/renal cell carcinoma (HCC/RCC)
East – August 8, 2023
Faculty Chair
Kirollos S. Hanna, PharmD, BCPS, BCOP
Minnesota Oncology
West – August 17, 2023
Faculty Chair
Kirollos S. Hanna, PharmD, BCPS, BCOP
Minnesota Oncology
More Information
- Virtual series
- East
More Information
- Virtual series
- West
REPORT SNAPSHOT
- A virtual, moderated roundtable discussion focusing on current treatment practices and future considerations for treatment of RCC and HCC
- Insights on the following therapies were obtained
- Management of TKI therapies in solid tumors
- Patient treatment within IDN pharmacies
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- Data collection was accomplished through use of audience response system questioning and moderated discussion
- The group of advisors is composed of clinical pharmacists, nurse practitioners, and/or pharmacy managers from states across the US
